[go: up one dir, main page]

DK0911340T3 - Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel - Google Patents

Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel

Info

Publication number
DK0911340T3
DK0911340T3 DK98119591T DK98119591T DK0911340T3 DK 0911340 T3 DK0911340 T3 DK 0911340T3 DK 98119591 T DK98119591 T DK 98119591T DK 98119591 T DK98119591 T DK 98119591T DK 0911340 T3 DK0911340 T3 DK 0911340T3
Authority
DK
Denmark
Prior art keywords
drug
preparation
carboxylic acid
acid amides
substituted isoquinoline
Prior art date
Application number
DK98119591T
Other languages
English (en)
Inventor
Klaus Dr Weidmann
Karl-Heinz Dr Baringhaus
Georg Dr Tschank
Ulrich Dr Werner
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of DK0911340T3 publication Critical patent/DK0911340T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DK98119591T 1997-10-20 1998-10-16 Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel DK0911340T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
DK0911340T3 true DK0911340T3 (da) 2005-11-07

Family

ID=7846053

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05004047T DK1538160T3 (da) 1997-10-20 1998-10-16 Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel
DK98119591T DK0911340T3 (da) 1997-10-20 1998-10-16 Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05004047T DK1538160T3 (da) 1997-10-20 1998-10-16 Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel

Country Status (24)

Country Link
US (1) US6093730A (da)
EP (2) EP0911340B1 (da)
JP (2) JP3782591B2 (da)
KR (1) KR100618922B1 (da)
CN (1) CN1117079C (da)
AR (1) AR013696A1 (da)
AT (2) ATE299148T1 (da)
AU (1) AU755714B2 (da)
BR (1) BR9804504B1 (da)
CA (2) CA2250664A1 (da)
CZ (1) CZ337298A3 (da)
DE (3) DE19746287A1 (da)
DK (2) DK1538160T3 (da)
ES (2) ES2328156T3 (da)
HU (1) HUP9802422A3 (da)
ID (1) ID21115A (da)
IL (1) IL126638A0 (da)
NO (1) NO312365B1 (da)
NZ (1) NZ332363A (da)
PL (1) PL192354B1 (da)
PT (1) PT911340E (da)
SG (1) SG87776A1 (da)
TR (1) TR199802106A2 (da)
ZA (1) ZA989505B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528649B2 (en) 2000-05-30 2003-03-04 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
WO2003053997A2 (en) * 2001-12-06 2003-07-03 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN101374815B (zh) 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
ES2619522T3 (es) * 2006-03-30 2017-06-26 Lg Electronics, Inc. Un método y un aparato para descodificar/codificar una señal de video multivisión
KR101084635B1 (ko) 2006-04-04 2011-11-18 피브로겐, 인크. Hif 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
ATE485264T1 (de) 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
AU2008241483B2 (en) 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
WO2009134750A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
NO2686520T3 (da) 2011-06-06 2018-03-17
JP6099644B2 (ja) * 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー, リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
HUE052128T2 (hu) 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
JP6129217B2 (ja) 2012-03-09 2017-05-17 フィブロジェン インコーポレイテッド Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
BR112015001101A2 (pt) 2012-07-16 2017-06-27 Fibrogen Inc formas cristalinas de um inibidor de prolil hidroxilase
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
KR20220164069A (ko) 2013-06-06 2022-12-12 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3466432B1 (en) 2014-05-15 2020-07-08 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
WO2016190420A1 (ja) * 2015-05-28 2016-12-01 日本たばこ産業株式会社 糖尿病性腎症を治療又は予防する方法
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3737693A4 (en) * 2018-01-09 2021-10-13 Cornell University PREVENTION AND TREATMENT OF ORGAN FIBROSIS
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
IL278533B1 (en) 2018-05-09 2025-10-01 Akebia Therapeutics Inc Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
EP3829623A4 (en) * 2018-08-03 2022-10-19 Cornell University METHODS OF REDUCING ABNORMAL SCAR FORMATION
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
JPH11302257A (ja) 1999-11-02
HK1019605A1 (en) 2000-02-18
DE19746287A1 (de) 1999-04-22
ES2245471T3 (es) 2006-01-01
AU8941398A (en) 1999-05-06
CN1218802A (zh) 1999-06-09
EP1538160B1 (de) 2009-06-03
EP0911340A2 (de) 1999-04-28
NZ332363A (en) 2000-04-28
SG87776A1 (en) 2002-04-16
NO984877D0 (no) 1998-10-19
NO984877L (no) 1999-04-21
EP1538160A1 (de) 2005-06-08
JP3782591B2 (ja) 2006-06-07
IL126638A0 (en) 1999-08-17
PT911340E (pt) 2005-09-30
PL329274A1 (en) 1999-04-26
BR9804504B1 (pt) 2009-01-13
HUP9802422A3 (en) 2002-02-28
CZ337298A3 (cs) 1999-05-12
AR013696A1 (es) 2001-01-10
NO312365B1 (no) 2002-04-29
BR9804504A (pt) 2001-05-22
EP0911340B1 (de) 2005-07-06
ZA989505B (en) 1999-04-20
CA2251647C (en) 2011-08-30
HU9802422D0 (en) 1998-12-28
CA2251647A1 (en) 1999-04-20
DE59814365D1 (de) 2009-07-16
KR19990037182A (ko) 1999-05-25
CN1117079C (zh) 2003-08-06
DE59812907D1 (de) 2005-08-11
ATE299148T1 (de) 2005-07-15
JP4691419B2 (ja) 2011-06-01
ID21115A (id) 1999-04-22
HUP9802422A2 (hu) 1999-08-30
CA2250664A1 (en) 1999-04-20
EP0911340A3 (de) 1999-07-07
DK1538160T3 (da) 2009-10-05
TR199802106A3 (tr) 1999-05-21
JP2006056894A (ja) 2006-03-02
ATE432940T1 (de) 2009-06-15
TR199802106A2 (xx) 1999-05-21
AU755714B2 (en) 2002-12-19
ES2328156T3 (es) 2009-11-10
KR100618922B1 (ko) 2007-04-25
PL192354B1 (pl) 2006-10-31
US6093730A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
DK0911340T3 (da) Substituerede isoquinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
NO975513L (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
NO20002486D0 (no) Sykliske aminderivater og deres anvendelse som legemidler
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
NO993003D0 (no) Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter
NO20011503D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20006029D0 (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
IS2076B (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
NO985368D0 (no) Substituerte imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende forbindelsene
NO981522D0 (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
DK0770059T3 (da) Substituerede benzamidiner, deres fremstilling og deres anvendelse som lægemidler
DK0903339T3 (da) Biphenylsulfonylcyanamid, fremgangsmåde til deres fremstilling og deres anvendelse som medikament
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
NO951147D0 (no) Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel
DK1157020T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-oler, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
NO981002L (no) Karboksylsyrederivater, deres fremstilling og anvendelse
NO20005549L (no) Substituerte sulfonylcyanamider, deres fremstilling og anvendelse som medikament
NO20015617L (no) Spiroimidazolderivater, deres fremstilling, deres anvendelse og farmasöytiske preparater som innbefatter slike derivater
DK1235809T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler